Lawrence Recht, MD

Professor of Neurology and, by courtesy, of Neurosurgery

Clinical Focus

Cancer > Neuro Oncology
Neurology

Academic Appointments

Professor - University Medical Line, Neurology
Professor - University Medical Line (By courtesy), Neurosurgery
Member, Bio-X
Member, Stanford Cancer Institute
Member, Wu Tsai Neurosciences Institute

Professional Education

Residency: University of Minnesota School of Medicine (1979) MN
Internship: University of Minnesota School of Medicine (1978) MN
Medical Education: Columbia Presbyterian Pediatric Residency Program (1977) NY
Fellowship: Memorial Sloan-Kettering Cancer Center (1984) NY
Board Certification: American Board of Psychiatry and Neurology, Neurology (1983)
Residency: New York Presbyterian Hospital (1982) NY
M.D., Columbia College of P&S, Medicine (1977)

Contact

Academic lrecht@stanford.edu Tel: (650) 725-8630 Fax: (650) 498-4686

Administrative Contact Karin Kao Administrative Assistant karinkao@stanford.edu Tel: 650 725-8630

Clinical Stanford Cancer Center Neuro-Oncology Clinic 875 Blake Wilbur Dr Clinic D MC 6510 Stanford CA 94305 Tel: (650) 498-6000 Fax: (650) 724-3556

Current Research and Scholarly Interests

Our laboratory focuses on two interrelated projects: (1) assessment of glioma development within the framework of the multistage model of carcinogenesis through utilization of the rodent model of ENU neurocarcinogenesis; and (2) assessment of stem cell specification and pluripotency using an embryonic stem cell model system in which neural differentiation is induced.

Clinical Trials

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Not Recruiting
More
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer. All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin. Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.

Stanford is currently not accepting patients for this trial. For more information, please contact Vani Jain, 650-723-1005.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema Not Recruiting
More
The purpose of this study is to examine the safety and efficacy of XERECEPT (human Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema.

Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Recht, 6507258630.
Lead Sponsor
Stanford Investigators
- Paul Graham Fisher, MD
- Lawrence Recht, MD
View full details
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Not Recruiting
More
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema). This study is specifically aimed at patients who require chronic high doses of dexamethasone to manage symptoms.

Stanford is currently not accepting patients for this trial. For more information, please contact Lynn Adler, 6507258630.
Lead Sponsor
Stanford Investigators
View full details
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Not Recruiting
More
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Kahn Recht, 650725863.
Lead Sponsor
Stanford Investigators
- Seema Nagpal, MD
- Lawrence Recht, MD
View full details
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT Not Recruiting
More
This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by immunohistochemical methods. A total of 10 patients will be imaged with 124I PET/CT (serial scans over 24 hour period) to determine radioiodide uptake and distribution in tumor tissue. Thyroid iodide uptake and retention will be blocked beginning one week prior to 124I PET/CT scan with thyroid hormone (T3) and methimazole (impedes organification). Tumor, organ and whole body dosimetry will be calculated in each patient.

Stanford is currently not accepting patients for this trial. For more information, please contact Marilyn Florero, 6507241953.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma Not Recruiting
More
To investigate the safety of delivering arsenic trioxide (ATO) in combination with stereotactic radiotherapy in recurrent malignant glioma by performing an open label, Phase I dose escalation trial. Results from this study will provide a basis for further study of ATO combined with radiation therapy as a radiosensitizer for malignant brain tumors in future Phase II studies.

Stanford is currently not accepting patients for this trial. For more information, please contact Laurie Tupper, 6504984143.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme Not Recruiting
More
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme

Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Recht, 6507258630.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Not Recruiting
More
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide

Stanford is currently not accepting patients for this trial. For more information, please contact Polly Young, 650-497-7499.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme Not Recruiting
More
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.

Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Recht, 6507258630.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme Not Recruiting
More
This, international, multi-center, Phase 2 study of verubulin will be conducted in patients with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two parts. Part A is an open-label dose finding study that will determine the safety and tolerability of verubulin in combination with standard treatment. Part B is a randomized open-label study that will investigate progression-free survival and overall survival of patients receiving verubulin, at the dose determined in Part A, in combination with standard treatment versus standard treatment alone.

Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Recht, 6507258630.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma Not Recruiting
More
This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent glioblastoma. Participants will be randomized 1:1 to receive either placebo plus bevacizumab every 3 weeks, or onartuzumab plus bevacizumab. Study treatment will continue until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.

Stanford is currently not accepting patients for this trial. For more information, please contact Sophie Bertrand, 6507234467.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Not Recruiting
More
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

Stanford is currently not accepting patients for this trial. For more information, please contact CCTO, 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Not Recruiting
More
This pilot phase I/II trial studies the side effects and best dose of plerixafor after radiation therapy and temozolomide and to see how well it works in treating patients with newly diagnosed high grade glioma. Plerixafor may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving plerixafor after radiation therapy and temozolomide may be an effective treatment for high grade glioma.

Stanford is currently not accepting patients for this trial. For more information, please contact Sophie Bertrand, 650-723-4467.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme Not Recruiting
More
The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.

Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Recht, 6507258630.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas Not Recruiting
More
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.

Stanford is currently not accepting patients for this trial. For more information, please contact Andrei Iagaru, 650-736-2859.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
- Andrei Iagaru
View full details
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Not Recruiting
More
The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.

Stanford is currently not accepting patients for this trial. For more information, please contact Lynn Adler, 6507258630.
Lead Sponsor
Stanford Investigators
View full details
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Not Recruiting
More
High Grade Gliomas, including anaplastic astrocytomas, anaplastic oligodendrogliomas and glioblastomas (GBM), are the most common and most aggressive primary brain tumors. Prognosis for patients with high-grade gliomas remains poor. The estimated median survival for patients with GBM is between 12 to 18 months. Recurrence after initial therapy with temozolomide and radiation is nearly universal. Since May 2009, the majority of patients in the US with an initial recurrence of high-grade glioma receive bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), which is thought to prevent angiogenesis in these highly vascular tumors. BEV has response rates from 32-62% and has improved overall median survival in patients with recurrent high-grade gliomas1. However, the response is short lived, and nearly 100% of patients eventually progress despite bevacizumab. No chemotherapeutic agent administered following progression through bevacizumab has made a significant impact on survival. Patients progress to death within 1-5 months after resistance develops. Therefore, patients with high-grade gliomas who have progressed through bevacizumab represent a population in dire need of a feasible and tolerable treatment. NKTR-102 is a topoisomerase I inhibitor polymer conjugate that was engineered by attaching irinotecan molecules to a polyethylene glycol (PEG) polymer using a biodegradable linker. Irinotecan released from NKTR-102 following administration is further metabolized to the active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN38), that causes DNA damage through inhibition of topoisomerase. The goal in designing NKTR-102 was to attenuate or eliminate some of the limiting side effects of irinotecan while improving efficacy by modifying the distribution of the agent within the body. The size and structure of NKTR-102 results in marked alteration in pharmacokinetic (PK) profile for the SN38 derived from NKTR-102 compared to that following irinotecan: the maximal plasma concentration (Cmax) is reduced 5- to 10-fold and the half-life (t1/2 ) of SN38 is increased from 2 days to approximately 50 days. This altered profile leads to constant exposure of the tumor to the active drug. In addition, the large NKTR-102 molecule does not freely pass out of intact vasculature, which may account for relatively higher concentrations of the compound and the active metabolites in tumor tissues in in vivo models, where the local vasculature may be relatively more permeable. A 145 mg/m2 dose of NKTR-102, the dose intended for use in this phase II clinical trial (and being used in the phase III clinical program), results in approximately the same plasma exposure to SN38 as a 350 mg/m2 dose of irinotecan, but exposure is protracted, resulting in continuous exposure between dosing cycles and lower Cmax. NKTR-102 was therefore developed as a new chemotherapeutic agent that may improve the clinical outcomes of patients.

Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Recht, 6507258630.
Lead Sponsor
Stanford Investigators
- Lawrence Recht, MD
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Neurology and Neurological Science
  NENS 299 (Aut, Win, Spr)
- Early Clinical Experience in Neurology and Neurological Sciences
  NENS 280 (Aut, Win, Spr)
- Graduate Research
  NENS 399 (Aut, Win, Spr)
- Medical Scholars Research
  NENS 370 (Aut, Win, Spr)
- Undergraduate Research
  NENS 199 (Aut, Win, Spr)

Stanford Advisees

Postdoctoral Faculty Sponsor
Abbas Khojasteh
Postdoctoral Research Mentor
Abraham Moses

All Publications

Profiles With Related Publications

close
Melissa L Bondy

Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics

443 Total Publications
close
Maximilian Diehn, MD, PhD

Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Clinical Focus
Cancer > Radiation Oncology, Cancer > Thoracic Oncology, Radiation Oncology, Radiation Therapy
Research Interests
My laboratory focuses on two main areas: 1) cancer stem cell biology and 2) novel biomarkers for identifying the presence of malignant cells (diagnostic), predicting outcome (prognostic), and predicting response to therapy (predictive). Areas of study include cancers of the lung, breast, and gastrointestinal system. Clinically I specialize in the treatment of lung cancer and applications of stereotactic ablative radiotherapy and perform both prospective and retrospective clinical studies.

437 Total Publications
close
Dean W. Felsher

Professor of Medicine (Oncology) and of Pathology
Research Interests
My laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.

217 Total Publications
close
Paul Graham Fisher, MD

Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Clinical Focus
Cancer > Neuro Oncology, Neurology - Child Neurology, Neuro-Oncology, Neurology
Research Interests
Clinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies, and childhood headaches.

273 Total Publications
close
Andrew Gentles

Assistant Professor (Research) of Pathology, of Medicine (BMIR) and, by courtesy, of Biomedical Data Science
Research Interests
Computational systems biology of human disease. Particular focus on integration of high-throughput datasets with each other, and with phenotypic information and clinical outcomes.

112 Total Publications
close
Olivier Gevaert

Associate Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science
Research Interests
My lab focuses on biomedical data fusion: the development of machine learning methods for biomedical decision support using multi-scale biomedical data. We primarily use methods based on regularized linear regression to accomplish this. We primarily focus on applications in oncology and neuroscience.

179 Total Publications
close
Amato J. Giaccia

Jack, Lulu and Sam Willson Professor, Professor of Radiation Oncology, Emeritus
Research Interests
During the last five years, we have identified several small molecules that kill VHL deficient renal cancer cells through a synthetic lethal screening approach. Another major interest of my laboratory is in identifying hypoxia-induced genes involved in invasion and metastases. We are also investigating how hypoxia regulates gene expression epigenetically.

403 Total Publications
close
Edward Graves

Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Research Interests
Applications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.

171 Total Publications
close
Seunggu J Han

Clinical Associate Professor, Neurosurgery

77 Total Publications
close
Quynh-Thu Le, MD

Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Clinical Focus
Cancer > Head and Neck Cancer, Cancer > Radiation Oncology, Lung Cancer - Radiation Oncology, Salivary Gland Tumors - Radiation Oncology, Head and Neck Cancers - Radiation Oncology, Larynx Cancer - Radiation Oncology, Radiation Oncology, Oral Cavity Cancer - Radiation Oncology, Sarcomas - Soft Tissue - Radiation Oncology, Skull Base Tumors - Radiation Oncology
Research Interests
My laboratory research interest focuses on the identification of biomarkers for prognosis in patients with head & neck or lung cancers. I am also conducting a number of clinical trials specifically in patients with head & neck cancers.

401 Total Publications
close
Lawrence Leung

Maureen Lyles D'Ambrogio Professor in the School of Medicine
Clinical Focus
Cancer > Hematology, Hematology
Research Interests
Our long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.

86 Total Publications
close
Gordon Li, MD

Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology - Head & Neck Surgery (OHNS)
Clinical Focus
Cancer > Neuro Oncology, Neurosurgery, Brain Tumors, radiosurgery, Minimally Invasive Surgical Procedures
Research Interests
1.) My laboratory studies the biology of brain tumors with the goal of developing novel therapeutics for the treatment of malignant brain tumors and translating that research into clinical trials.
2.) My clinical interests include improving surgical techniques for brain tumor surgery, immunotherapy for the treatment of glioblastoma, and novel uses for stereotactic radiosurgery.

206 Total Publications